1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
China Cancer Drug Market: Size, Trends & Forecasts (2018-2022)

China Cancer Drug Market: Size, Trends & Forecasts (2018-2022)

  • June 2018
  • 70 pages
  • ID: 5442691
  • Format: PDF
  • By Daedal Research


Table of Contents

Search Inside

Scope of the Report
The report entitled “China Cancer Drug Market: Size, Trends & Forecasts (2018-2022)”, provides analysis of the China cancer drug market, with detailed analysis of market size and growth, and value of the industry. The analysis includes the market by value, by cases and incidence ratio.

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall China cancer drug market has also been forecasted for the years 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Celgene, Novartis, Roche and Johnson & Johnson are some of the key players operating in the China cancer drug market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.

Company Coverage
Johnson & Johnson

Executive Summary
Cancer is a complex disease where uncontrolled growth of abnormal cells arises. Cancer is the process where new cell formation slows or start dividing, and form lumps. Cancer cells are different from normal cells. Cancer cells ignores signal of the body, evade the immune system and do not specialize in functioning.

There are various types of cancer in the world such as prostate cancer, lung & bronchus cancer, colon & rectum cancer, bladder cancer, breast cancer, kidney and renal pelvis cancer, thyroid cancer, endometrial cancer and others. For different cancer, different types of treatments are available in the market such as chemotherapy, surgery, radiation therapy, targeted therapies, immunotherapy, hormonal therapy, angiogenesis inhibitors and synthetic lethality.

There are different categories of anti-cancer drugs such as classic cytotoxic agents (alkylating agents, antimetabolites, and anti-microtubule agents, etc.), target-based anticancer drugs (selective or semi-selective), biologics or immunotherapy and hormones and hormone antagonists.

Chemotherapy is the most common cancer treatment. But there are few side-effects which are associated with chemotherapy treatment displaying different side effcets on different patients such as fatigue, hair loss, diarrhea, weight change, easy bruising and bleeding, nausea and vomiting, etc.

The China Cancer Drug Market is expected to increase at high growth rates during the forecasted period (2018-2022). The china cancer drug market is supported by various growth drivers, such as rising aging population, stress resulting in increasing cancer cases, introduction of cutting edge therapy, rising incidence ratio, etc. The market faces certain challenges, such as, cross-border consultation, failure of clinical trial, etc. few new market trends are also provided such as, accelerated approval for advanced cancer drugs, combination therapy, etc.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Cyclin Dependent Kinase 2 - Pipeline Review, H2 2019

Cyclin Dependent Kinase 2 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Cyclin Dependent Kinase 2 - Pipeline Review, H2 2019SummaryCyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC pipeline Target constitutes close to ...

Cellular Tumor Antigen p53 - Pipeline Review, H2 2019

Cellular Tumor Antigen p53 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Cellular Tumor Antigen p53 - Pipeline Review, H2 2019SummaryCellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close to 27 molecules. ...

Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020

Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020

  • $ 3500
  • January 2020

Indoleamine 2,3 Dioxygenase 1 - Pipeline Review, H1 2020SummaryIndoleamine 2,3 Dioxygenase 1 (Indoleamine Pyrrole 2,3 Dioxygenase 1 or IDO1 or EC - Indoleamine-pyrrole 2, 3-dioxygenase 1 is ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on